APEX
PUBLIC COMPANY PAGE · SEC DATA

Johnson & Johnson, in one read.

What the company reports, what changed and what to investigate next. Every figure carries its period, its document and its date.

JNJNYSESEC industry classification: Pharmaceutical PreparationsCIK 0000200406

Snapshot taken on Nov 5, 2026. Data is not updated in real time: when the company files a new report, the page is regenerated.

Opens the no-account trial with this asset already filled in. No card.

Partial coverage · No AI-generated narrative

The business

Excerpt from the company filing · original language

The Company closely monitors these proposals as they arise in the countries where it operates.

Period ended Dec 28, 2025

Source and period

10-K · Business (source excerpt) · Dec 28, 2025

View on SEC EDGAR ↗

The business at a glance

  • Revenue

    25.4B USD

    Quarter · Sep 27, 2026

    Comparable period: Sep 28, 2025 · +5.9 %

    Source and period

    10-Q · RevenueFromContractWithCustomerExcludingAssessedTax · Sep 27, 2026

    View on SEC EDGAR ↗

    10-Q · RevenueFromContractWithCustomerExcludingAssessedTax · Sep 28, 2025

    View on SEC EDGAR ↗
  • Net income

    210M USD

    Quarter · Sep 27, 2026

    Comparable period: Sep 28, 2025 · -95.9 %

    Source and period

    10-Q · NetIncomeLoss · Sep 27, 2026

    View on SEC EDGAR ↗

    10-Q · NetIncomeLoss · Sep 28, 2025

    View on SEC EDGAR ↗
  • Operating cash flow

    2.5B USD

    Quarter · Mar 29, 2026 · Historical figure; check its date

    Comparable period: Mar 30, 2025 · -39.8 %

    Source and period

    10-Q · NetCashProvidedByUsedInOperatingActivities · Mar 29, 2026

    View on SEC EDGAR ↗

    10-Q · NetCashProvidedByUsedInOperatingActivities · Mar 30, 2025

    View on SEC EDGAR ↗
  • Cash and equivalents

    16.9B USD

    Balance as of · Sep 27, 2026

    Comparable period: Sep 28, 2025 · -7.2 %

    Source and period

    10-Q · CashAndCashEquivalentsAtCarryingValue · Sep 27, 2026

    View on SEC EDGAR ↗

    10-Q · CashAndCashEquivalentsAtCarryingValue · Sep 28, 2025

    View on SEC EDGAR ↗

Closing price over time

JNJ close per period, in the quoted currency

0100200276
1986199219982004201020162022

Jan 1985 → Nov 2026

Yahoo Finance series with a quarterly close, retrieved on Nov 5, 2026. Historical price, not a live quote nor a forecast.

What changed

Why it could matter

Interpretation

Revenue increased versus the comparable period. This does not establish that growth will continue.

Source and period

10-Q · RevenueFromContractWithCustomerExcludingAssessedTax · Sep 27, 2026

View on SEC EDGAR ↗

10-Q · RevenueFromContractWithCustomerExcludingAssessedTax · Sep 28, 2025

View on SEC EDGAR ↗

Questions worth asking

  • What explains the revenue change at JNJ, and which drivers could recur?
  • Do JNJ’s earnings convert into cash, and do they depend on exceptional items?
  • What commitments and liquidity needs does JNJ have?
Financial detail
MetricPeriodValuevs. prior yearFiled
Gross profitQuarter · Sep 27, 202617.3B USD+3.7 %Oct 21, 2026
Operating incomeQuarter · Mar 29, 20155.8B USD+3.1 %May 1, 2015
Diluted EPSQuarter · Sep 27, 20260.09 USD-95.8 %Oct 21, 2026
Capital expenditureQuarter · Mar 29, 20261B USD+31.9 %Apr 22, 2026
Long-term debtBalance as of · Sep 27, 202635.8B USD-9.2 %Oct 21, 2026
Shareholders’ equityBalance as of · Sep 27, 202681.5B USD+2.8 %Oct 21, 2026
Margins calculated by APEX

Calculated on same-period figures and declared as APEX’s own calculation, not as reported data.

Gross marginFiscal year · Dec 28, 202567.9 %
Net marginFiscal year · Dec 28, 202528.5 %
Gross marginQuarter · Sep 27, 202668.1 %
Net marginQuarter · Sep 27, 20260.8 %
What this page does not cover
  • Quotes and valuation: not published here; distribution rights have not been established.
  • Valuation multiples: not available without a quote.
  • Linked documents have not been read in full.
  • Revenue by segment or geography: not in the SEC structured data.
  • Management guidance: not available in structured form.
  • Earnings call transcripts: not licensed.
  • Analyst consensus: not licensed.
Sources and method

SEC XBRL facts. Comparisons use the same accounting concept and compatible periods. A filing alone does not establish causes or consequences. This is not an investment recommendation.

Data retrieved on: Nov 5, 2026 · Period ended Sep 27, 2026

What would I have today if I had invested in JNJ?

Understand the terms

Other public company pages

APEX does not execute trades or guarantee results. Investing involves risk of loss.